Oncotelic Therapeutics(OTLC)

Focus: Oncotelic Therapeutics is a publicly-traded biotech focused on transforming growth factor beta 2 inhibition for oncology and infectious diseases. The company operates at pre-revenue scale with minimal cash reserves and a single lead asset in clinical development.

Oncology Infectious Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Total Funding

$3M

Open Jobs

About Oncotelic Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Oncotelic Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$70K

FY2024

Pipeline & Clinical Trials

OT-101

COVID-19

Phase 2

Clinical Trials (1)

NCT04801017A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

Phase 2

Help build intelligence for Oncotelic Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on novel TGF-β2 inhibitor mechanism with potential in pancreatic cancer and mesothelioma, high-mortality indications
Public company status provides equity liquidity and potential access to capital markets, reducing funding uncertainty versus private startups
Early-stage pipeline allows significant individual impact on drug development strategy and program prioritization

Watch Out For

Extreme financial distress: $7.9M net loss on $70K revenue in FY2024 with only $170K cash on hand—company may face imminent solvency challenges
Zero current job openings and minimal headcount data suggest potential hiring freeze or organizational downsizing, limiting career advancement opportunities
No approved products, zero publications, and early clinical stage (Phase 2/3 lead program) mean years before potential value realization or exit

Generated by Claude from Oncotelic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

OT-101

Malignant Pleural Mesothelioma

Phase 2

Clinical Trials (1)

NCT05425576OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2

OT-101

Pancreatic Ductal Adenocarcinoma

Phase 2/3

Clinical Trials (1)

NCT06079346A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

Phase 2/3